BICYCLE THERAPEUTICS PLC-ADR (BCYC) Stock News
NASDAQ:BCYC - Nasdaq - US0887861088 - ADR - Currency: USD
BCYC Latest News, Press Relases and Analysis
Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Here's Why GE HealthCare Stock Sank in April
Hospital capital equipment spending in China continues to be sluggish. An improvement in the trade conflict will create upside potential for GE HealthCare, and management believes China is a long-term growth opportunity.
State Street Report Shows Big Slump in April ETF Inflows
- Investors added just $62 billion to ETFs in April, the lowest since 2024. - Risk-off sentiment drove a record $11 billion of outflows from sector ETFs. - Short-term government bond funds saw their second-highest inflows ever.
Is Vertical Aerospace Ltd. (EVTL) the Best Small Cap Stock to Buy with the Biggest Upside Potential?
We recently published a list of Top 11 Small Cap Stocks to Buy with Biggest Upside Potential. In this article, we are going to take a look at where Vertical Aerospace Ltd. (NYSE:EVTL) stands against other top small cap stocks to buy with biggest upside potential. On April 24, Jill Carey Hall, BofA Securities head […]
Is Bicycle Therapeutics plc (BCYC) the Best Small Cap Stock to Buy with the Biggest Upside Potential?
We recently published a list of Top 11 Small Cap Stocks to Buy with Biggest Upside Potential. In this article, we are going to take a look at where Bicycle Therapeutics plc (NASDAQ:BCYC) stands against other top small cap stocks to buy with biggest upside potential. On April 24, Jill Carey Hall, BofA Securities head […]
Chart of the Week: '10x Money Multiplier' for Bitcoin Could Take Wall Street by Storm
Publicly traded firms relentlessly buying bitcoin for their balance sheet could result in 'significant buy pressure.'
Bicycle Therapeutics price target lowered to $15 from $40 at Barclays
Barclays lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $15 from $40 and keeps an Overweight rating on the shares following the Q1 report. The firm says the company’s pipeline catalysts remain on track. “Out of an abundance of caution,” the analyst increased the stock’s discount rate, removed deeper pipeline value, and trimmed penetration, driving the target cut. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bicycle Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Bicycle Therapeutics Announces New Board and Key Clinical Leadership Appointments
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results
Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones
Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification
Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update
Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
